{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:01:40Z","timestamp":1791576100046,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5-6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.2119\/molmed.2011.00076","type":"journal-article","created":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T14:12:16Z","timestamp":1306419136000},"page":"466-472","source":"Crossref","is-referenced-by-count":100,"title":["Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir"],"prefix":"10.1186","volume":"17","author":[{"given":"Shay","family":"Matalon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A","family":"Dinarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,15]]},"reference":[{"key":"1705466_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1086\/317641","volume":"183","author":"H Imamichi","year":"2001","unstructured":"Imamichi H, et al. (2001) Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J. Infect. Dis. 183:36\u201350.","journal-title":"J. Infect. Dis."},{"key":"1705466_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1172\/JCI10565","volume":"106","author":"L Zhang","year":"2000","unstructured":"Zhang L, et al. (2000) Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J. Clin. Invest. 106:839\u201345.","journal-title":"J. Clin. Invest."},{"key":"1705466_CR3","doi-asserted-by":"publisher","first-page":"15109","DOI":"10.1073\/pnas.96.26.15109","volume":"96","author":"RT Davey Jr.","year":"1999","unstructured":"Davey RT Jr, et al. (1999) HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Nat\u00ef. Acad. Sci. U. S. A. 96:15109\u201314.","journal-title":"Proc. Nat\u00ef. Acad. Sci. U. S. A."},{"key":"1705466_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/77481","volume":"6","author":"TW Chun","year":"2000","unstructured":"Chun TW, et al. (2000) Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6:757\u201361.","journal-title":"Nat. Med."},{"key":"1705466_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/387183a0","volume":"387","author":"TW Chun","year":"1997","unstructured":"Chun TW, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 387:183\u20138.","journal-title":"Nature"},{"key":"1705466_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi D, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1295\u2013300.","journal-title":"Science"},{"key":"1705466_CR7","doi-asserted-by":"publisher","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","volume":"95","author":"TW Chun","year":"1998","unstructured":"Chun TW, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:8869\u201373.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1705466_CR8","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1086\/315113","volume":"180","author":"F Lori","year":"1999","unstructured":"Lori F, et al. (1999) Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before serocon-version is associated with normalized immune parameters and limited viral reservoir. J. Infect. Dis. 180:1827\u201332.","journal-title":"J. Infect. Dis."},{"key":"1705466_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nm880","volume":"9","author":"JD Siliciano","year":"2003","unstructured":"Siliciano JD, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727\u20138.","journal-title":"Nat. Med."},{"key":"1705466_CR10","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJM199905273402101","volume":"340","author":"L Zhang","year":"1999","unstructured":"Zhang L, et al. (1999) Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340:1605\u201313.","journal-title":"N. Engl. J. Med."},{"key":"1705466_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/71577","volume":"6","author":"B Ramratnam","year":"2000","unstructured":"Ramratnam B, et al. (2000) The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6:82\u20135.","journal-title":"Nat. Med."},{"key":"1705466_CR12","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1172\/JCI26197","volume":"115","author":"TW Chun","year":"2005","unstructured":"Chun TW, et al. (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115:3250\u20135.","journal-title":"J. Clin. Invest."},{"key":"1705466_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00126334-200401010-00004","volume":"35","author":"B Ramratnam","year":"2004","unstructured":"Ramratnam B, et al. (2004) Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J. Acquit. Immune Defic. Syndr. 35:33\u20137.","journal-title":"J. Acquit. Immune Defic. Syndr."},{"key":"1705466_CR14","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1086\/518250","volume":"195","author":"TW Chun","year":"2007","unstructured":"Chun TW, et al. (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195:1762\u20134.","journal-title":"J. Infect. Dis."},{"key":"1705466_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1023\/A:1011091300321","volume":"21","author":"RM Praag van","year":"2001","unstructured":"van Praag RM, et al. (2001) OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J. Clin. Immunol. 21:218\u201326.","journal-title":"J. Clin. Immunol."},{"key":"1705466_CR16","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1097\/00002030-199912030-00012","volume":"13","author":"JM Prins","year":"1999","unstructured":"Prins JM, et al. (1999) Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. Aids. 13:2405\u201310.","journal-title":"Aids"},{"key":"1705466_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1086\/338123","volume":"185","author":"M Dybul","year":"2002","unstructured":"Dybul M, et al. (2002) Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J. Infect. Dis. 185:61\u20138.","journal-title":"J. Infect. Dis."},{"key":"1705466_CR18","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1017\/S1462399409000970","volume":"11","author":"MC Bowman","year":"2009","unstructured":"Bowman MC, Archin NM, Margolis DM. (2009) Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev. Mol. Med. 11:e6.","journal-title":"Expert Rev. Mol. Med."},{"key":"1705466_CR19","doi-asserted-by":"publisher","first-page":"e3305","DOI":"10.1371\/journal.pone.0003305","volume":"3","author":"TA Tran","year":"2008","unstructured":"Tran TA, et al. (2008) Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One. 3:e3305.","journal-title":"PLoS One"},{"key":"1705466_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1084\/jem.188.2.287","volume":"188","author":"AM Thornton","year":"1998","unstructured":"Thornton AM, Shevach EM. (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287\u201396.","journal-title":"J. Exp. Med."},{"key":"1705466_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1097\/00002030-200207260-00004","volume":"16","author":"HJ Stellbrink","year":"2002","unstructured":"Stellbrink HJ, et al. (2002) Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). Aids. 16:1479\u201387.","journal-title":"Aids"},{"key":"1705466_CR22","first-page":"2562","volume":"118","author":"P Reddy","year":"2008","unstructured":"Reddy P, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118:2562\u201373.","journal-title":"J. Clin. Invest."},{"key":"1705466_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/nrd3031","volume":"8","author":"L Wang","year":"2009","unstructured":"Wang L, de Zoeten EF, Greene MI, Hancock WW. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat. Rev. Drug. Discov. 8:969\u201381.","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1705466_CR24","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1002\/j.1460-2075.1993.tb05994.x","volume":"12","author":"E Verdin","year":"1993","unstructured":"Verdin E, Paras P Jr, Van Lint C. (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 12:3249\u20133259.","journal-title":"EMBO J."},{"key":"1705466_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/sj.emboj.7600900","volume":"25","author":"SA Williams","year":"2006","unstructured":"Williams SA, et al. (2006) NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139\u201349.","journal-title":"EMBO J."},{"key":"1705466_CR26","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1128\/JVI.02585-08","volume":"83","author":"KS Keedy","year":"2009","unstructured":"Keedy KS, et al. (2009) A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J. Virol. 83:4749\u201356.","journal-title":"J. Virol."},{"key":"1705466_CR27","doi-asserted-by":"publisher","first-page":"6790","DOI":"10.1128\/JVI.74.15.6790-6799.2000","volume":"74","author":"JJ Coull","year":"2000","unstructured":"Coull JJ, et al. (2000) The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74:6790\u20139.","journal-title":"J. Virol."},{"key":"1705466_CR28","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1128\/MCB.22.12.4043-4052.2002","volume":"22","author":"SC Hsia","year":"2002","unstructured":"Hsia SC, Shi YB. (2002) Chromatin disruption and histone acetylation in regulation of the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptor. Mol. Cell. Biol. 22:4043\u201352.","journal-title":"Mol. Cell. Biol."},{"key":"1705466_CR29","doi-asserted-by":"publisher","first-page":"10914","DOI":"10.1128\/JVI.01208-07","volume":"81","author":"G Jiang","year":"2007","unstructured":"Jiang G, Espeseth A, Hazuda DJ, Margolis DM. (2007) c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J. Virol. 81:10914\u201323.","journal-title":"J. Virol."},{"key":"1705466_CR30","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1038\/sj.emboj.7601928","volume":"26","author":"M Tyagi","year":"2007","unstructured":"Tyagi M, Karn J. (2007) CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 26:4985\u201395.","journal-title":"EMBO J."},{"key":"1705466_CR31","doi-asserted-by":"publisher","first-page":"12495","DOI":"10.1074\/jbc.M511773200","volume":"281","author":"K Imai","year":"2006","unstructured":"Imai K, Okamoto T. (2006) Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J. Biol. Chem. 281:12495\u2013505.","journal-title":"J. Biol. Chem."},{"key":"1705466_CR32","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1093\/emboj\/cdg631","volume":"22","author":"M Lusic","year":"2003","unstructured":"Lusic M, Marcello A, Cereseto A, Giacca M. (2003) Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J. 22:6550\u201361.","journal-title":"EMBO J."},{"key":"1705466_CR33","doi-asserted-by":"publisher","first-page":"12198","DOI":"10.1128\/JVI.78.22.12198-12206.2004","volume":"78","author":"S Thierry","year":"2004","unstructured":"Thierry S, et al. (2004) Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter. J. Virol. 78:12198\u2013206.","journal-title":"J. Virol."},{"key":"1705466_CR34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","volume":"366","author":"G Lehrman","year":"2005","unstructured":"Lehrman G, et al. (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 366:549\u201355.","journal-title":"Lancet"},{"key":"1705466_CR35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1086\/511823","volume":"195","author":"JD Siliciano","year":"2007","unstructured":"Siliciano JD, et al. (2007) Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195:833\u201336.","journal-title":"J. Infect. Dis."},{"key":"1705466_CR36","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/QAD.0b013e3282fd6ddc","volume":"22","author":"N Sagot-Lerolle","year":"2008","unstructured":"Sagot-Lerolle N, et al. (2008) Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. Aids. 22:1125\u20139.","journal-title":"Aids"},{"key":"1705466_CR37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1097\/QAD.0b013e3282fd6df4","volume":"22","author":"NM Archin","year":"2008","unstructured":"Archin NM, et al. (2008) Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. Aids. 22:1131\u20135.","journal-title":"Aids"},{"key":"1705466_CR38","doi-asserted-by":"publisher","first-page":"e9390","DOI":"10.1371\/journal.pone.0009390","volume":"5","author":"NM Archin","year":"2010","unstructured":"Archin NM, et al. (2010) Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 5:e9390.","journal-title":"PLoS One"},{"key":"1705466_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0b013e3181d3dca3","volume":"54","author":"S Matalon","year":"2010","unstructured":"Matalon S, et al. (2010) The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 54:1\u20139.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"1705466_CR40","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 12:1247\u201352.","journal-title":"Oncologist"},{"key":"1705466_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/aid.2008.0191","volume":"25","author":"NM Archin","year":"2009","unstructured":"Archin NM, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses. 25:207\u201312.","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"1705466_CR42","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1089\/aid.2008.0294","volume":"25","author":"LC Edelstein","year":"2009","unstructured":"Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP. (2009) Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res. Hum. Retroviruses. 25:883\u20137.","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"1705466_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2119\/molmed.2011.00020","volume":"17","author":"A Furlan","year":"2011","unstructured":"Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353\u2013362.","journal-title":"Mol. Med."},{"key":"1705466_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2119\/molmed.2011.00030","volume":"17","author":"J Vojinovic","year":"2011","unstructured":"Vojinovic J, Damjanov N. (2011) HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol. Med. 17:397\u2013403.","journal-title":"Mol. Med."},{"key":"1705466_CR45","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"N Khan","year":"2008","unstructured":"Khan N, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409:581\u20139.","journal-title":"Biochem. J."},{"key":"1705466_CR46","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","volume":"81","author":"P Gimsing","year":"2008","unstructured":"Gimsing P, et al. (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 81:170\u20136.","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"1705466_CR47","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","volume":"46","author":"Helen J. Mackay","year":"2010","unstructured":"Mackay HJ, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur. J. Cancer. 46:1573-9.","journal-title":"European Journal of Cancer"},{"key":"1705466_CR48","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1097\/QAD.0b013e32832ec1dc","volume":"23","author":"NM Archin","year":"2009","unstructured":"Archin NM, et al. (2009) Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. Aids. 23:1799\u2013806.","journal-title":"Aids"},{"key":"1705466_CR49","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1091\/mbc.e05-04-0354","volume":"16","author":"A Valenzuela-Fernandez","year":"2005","unstructured":"Valenzuela-Fernandez A, et al. (2005) Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection. Mol. Biol. Cell 16:5445\u201354.","journal-title":"Mol. Biol. Cell"},{"key":"1705466_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0163-7258(80)90009-1","volume":"10","author":"PL Morselli","year":"1980","unstructured":"Morselli PL, Franco-Morselli R. (1980) Clinical pharmacokinetics of antiepileptic drugs in adults. Pharmacol. Ther. 10:65\u2013101.","journal-title":"Pharmacol. Ther."},{"key":"1705466_CR51","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","volume":"5","author":"LH Kuller","year":"2008","unstructured":"Kuller LH, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5:e203.","journal-title":"PLoS Med."},{"key":"1705466_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/QAI.0b013e3181f7f61a","volume":"56","author":"JV Baker","year":"2011","unstructured":"Baker JV, et al. (2011) Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 56:36\u201343.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"1705466_CR53","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1006\/viro.1993.1505","volume":"196","author":"MA Laughlin","year":"1993","unstructured":"Laughlin MA, et al. (1993) Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology. 196:496\u2013505.","journal-title":"Virology"},{"key":"1705466_CR54","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/j.1460-2075.1996.tb00449.x","volume":"15","author":"C Lint Van","year":"1996","unstructured":"Van Lint C, Emiliani S, Ott M, Verdin E. (1996) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15:1112\u201320.","journal-title":"EMBO J."},{"key":"1705466_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/aid.1997.13.187","volume":"13","author":"M Witvrouw","year":"1997","unstructured":"Witvrouw M, et al. (1997) Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Res. Hum. Retroviruses. 13:187\u201392.","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"1705466_CR56","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1128\/MCB.18.5.2535","volume":"18","author":"A Kharroubi El","year":"1998","unstructured":"El Kharroubi A, Piras G, Zensen R, Martin MA. (1998) Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol. Cell. Biol. 18:2535\u201344.","journal-title":"Mol. Cell. Biol."},{"key":"1705466_CR57","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/00002030-200405210-00003","volume":"18","author":"L Ylisastigui","year":"2004","unstructured":"Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. (2004) Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. Aids. 18:1101\u20138.","journal-title":"Aids"},{"key":"1705466_CR58","doi-asserted-by":"publisher","first-page":"6782","DOI":"10.1074\/jbc.M807898200","volume":"284","author":"X Contreras","year":"2009","unstructured":"Contreras X, et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284:6782\u20139.","journal-title":"J. Biol. Chem."},{"key":"1705466_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1742-4690-6-52","volume":"6","author":"A Savarino","year":"2009","unstructured":"Savarino A, et al. (2009) \u201cShock and kill\u201d effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology. 6:52.","journal-title":"Retrovirology"},{"key":"1705466_CR60","doi-asserted-by":"publisher","first-page":"e6093","DOI":"10.1371\/journal.pone.0006093","volume":"4","author":"S Reuse","year":"2009","unstructured":"Reuse S, et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One. 4:e6093.","journal-title":"PLoS One"},{"key":"1705466_CR61","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1097\/QAD.0b013e328330342c","volume":"23","author":"M Shehu-Xhilaga","year":"2009","unstructured":"Shehu-Xhilaga M, et al. (2009) The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. Aids. 23:2047\u201350.","journal-title":"Aids"},{"issue":"4","key":"1705466_CR62","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/QAD.0b013e328333bfa1","volume":"24","author":"Byeong-Sun Choi","year":"2010","unstructured":"Choi BS, et al. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1. Aids. 24:609-11.","journal-title":"AIDS"},{"key":"1705466_CR63","doi-asserted-by":"crossref","unstructured":"Yin H, Zhang Y, Zhou X, Zhu H. (2010) Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol. Biol. Rep. 2010, Dec 23 [Epub ahead of print].","DOI":"10.1007\/s11033-010-0653-6"},{"key":"1705466_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1742-4690-6-111","volume":"6","author":"L Colin","year":"2009","unstructured":"Colin L, Van Lint C. (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 6:111.","journal-title":"Retrovirology"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.crossref.org\/molmed.2011.00076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2011.00076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T06:34:47Z","timestamp":1560234887000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2011.00076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,15]]},"references-count":64,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["1705466"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2011.00076","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,15]]}}}